The treatment modality and prognosis of breast cancers are dependent on factors, such as metastases, tumor size, lymph node involvement, histological grade, estrogen (ER) and human epidermal growth factor type 2 and progesterone (PgR) receptors, as well as the proliferative marker, Ki67. Here, ESR1 is linked to breast carcinoma.